drugset / Trial / NCT04008121

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

NCT04008121

Phase 0 Recruiting 10 enrolled MediBeacon
NaSingle-groupOpen-labelDiagnostic

Summary

The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.

Timeline

Start
2025-11-06
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluorescein Diagnostic / imaging agent 500 mg Intravenous
Subject Relmapirazin Diagnostic / imaging agent 4 unknown Intravenous